Search Result

Results for "

Integrin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (290) 5-HT Receptor (1) ADC Antibody (1) Akt (5) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (29) Aryl Hydrocarbon Receptor (3) Autophagy (9) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (2) Biochemical Assay Reagents (5) Btk (1) c-Kit (1) C-type Lectin-like Receptors (CTLRs) (1) Caspase (4) CD22 (1) Chemerin Receptor (1) Complement System (7) Discoidin Domain Receptor (3) DNA Methyltransferase (1) DNA/RNA Synthesis (3) Dopamine Receptor (1) Drug Derivative (1) Drug Intermediate (8) Drug Isomer (4) EGFR (1) Elastase (1) Endogenous Metabolite (9) Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (1) Endothelin Receptor (2) ERK (9) Factor Xa (1) FAK (14) Fluorescent Dye (3) Free Fatty Acid Receptor (2) Glutaminase (1) Glycoprotein VI (1) HIF/HIF Prolyl-Hydroxylase (1) HSP (4) IFNAR (2) IKK (1) Interleukin Related (3) Isotope-Labeled Compounds (6) JNK (1) Liposome (9) MDM-2/p53 (3) MMP (3) Molecular Glues (1) mRNA (2) mTOR (1) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (2) Orthopoxvirus (1) Osteopontin (1) P-selectin (1) p38 MAPK (4) PAI-1 (1) PANoptosis (1) PD-1/PD-L1 (4) PI3K (4) Potassium Channel (3) Radionuclide-Drug Conjugates (RDCs) (5) Raf (1) RAR/RXR (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (16) RIP kinase (1) Ser/Thr Kinase (2) Sialyltransferase (3) Small Interfering RNA (siRNA) (1) Src (9) STAT (3) Syk (2) TGF-beta/Smad (2) TGF-β Receptor (4) TNF Receptor (1) Transmembrane Glycoprotein (1) VEGFR (4) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (181) Cardiovascular Disease (44) Endocrinology (1) Infection (11) Inflammation/Immunology (133) Metabolic Disease (16) Neurological Disease (25)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Pegylated Lipids (9) Chemokine & Receptors (1) mRNA (2) siRNA drugs (1) siRNAs (1)

349

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

119

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Integrin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16141

Cilengitide Maximum Cited Publications 70 Publications Verification EMD 121974	Integrin Autophagy Apoptosis STAT PD-1/PD-L1	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Cilengitide (EMD 121974) is a BBB-permeable *integrins* antagonist with IC₅₀s of 0.61 nM (α_νβ₃), 8.4 nM (α_νβ₅) and 14.9 nM (α₅β₁), respectively. Cilengitide inhibits the binding of α_νβ₃ and α_νβ₅ to Vitronectin with IC₅₀s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .

HY-P0023

Cyclo(-RGDfK) Maximum Cited Publications 27 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC₅₀ of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P9911

Vedolizumab 3 Publications Verification Anti-Human lymphocyte α4β7 Integrin, Humanized Antibody; LDP-02; MLN-002	Integrin	Inflammation/Immunology Cancer
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 *integrin* for the treatment of ulcerative colitis and Crohn's disease.

HY-P0023A

Cyclo(-RGDfK) TFA Maximum Cited Publications 27 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-177080

Emvistegrast GS-1427	Integrin	Inflammation/Immunology
Emvistegrast (GS-1427) is a quinolone derivative. Emvistegrast is also an inhibitor of α4β7 integrin. Emvistegrast can be used to investigate diseases mediated by α4β7 integrin, such as inflammatory bowel disease .

HY-134130

Integrin modulator 1 2 Publications Verification	Integrin	Inflammation/Immunology
Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC₅₀ of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC₅₀ of 12.9 nM .

HY-P9911A

*Vedolizumab (anti-α4β7-integrin)*	Integrin	Inflammation/Immunology
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 *integrin* for the treatment of ulcerative colitis and Crohn's disease .

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Integrin Endogenous Metabolite	Cancer
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-15770

TR-14035 5+ Cited Publications	Integrin	Inflammation/Immunology
TR-14035 is a orally active dual α₄β₇/α₄β₁ integrin antagonist, with IC₅₀ s of 7 nM and 87 nM for α₄β₇ and α₄β₁, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .

HY-100445A

*αvβ1 integrin-IN-1 TFA* 5+ Cited Publications	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

HY-P990203

*Anti-Mouse LPAM-1/Integrin* α4β7 Antibody (DATK32)** 1 Publications Verification	Integrin	Inflammation/Immunology
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived anti-LPAM-1/Integrin α4β7 IgG2a, κ type antibody inhibitor. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) specifically reacts with both chains of the α4β7 heterodimer and blocks the adhesion to immobilized mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) suppresses the proliferation and cytokine secretion of CD8+ T cells. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) decreases Peyer’s patches and follicular B cells in mice. Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) can be used for the researches of inflammation, such as ulcerative colitis .

HY-P5133

Synstatin (92-119) 1 Publications Verification SSTN92-119	Integrin	Cancer
Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .

HY-P1408

Obtustatin 4 Publications Verification	Integrin VEGFR	Cancer
Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .

HY-175287

*α5β1 integrin* agonist-2**	Integrin	Cancer
α5β1 integrin agonist-2 (Compound 2) is a selective α5β1 integrin agonist (EC₅₀ = 45.98 nM). α5β1 integrin agonist-2 induces integrin activation. α5β1 integrin agonist-2 is applicable to the research of leukemia .

HY-145363

*αvβ5 integrin-IN-1* 1 Publications Verification	Integrin	Cancer
αvβ5 integrin-IN-1 (Compound 12) is a selective αvβ5 inhibitor (pIC₅₀ = 8.2). αvβ5 integrin-IN-1 exhibits 800-fold selectivity for αvβ5 versus αvβ3 .

HY-100445

*αvβ1 integrin-IN-1* 5+ Cited Publications	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC₅₀ of 0.63 nM. Antifibrotic effects .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-P3732

RGD-4C	Integrin	Cancer
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .

HY-P99296

Intetumumab CNTO 95; Anti-Human CD51 Recombinant Antibody	Integrin Apoptosis	Cancer
Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a K_d value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .

HY-115677

ILK-IN-3	Ser/Thr Kinase	Cancer
ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with *alphav-integrins* and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-P5098

E(c(RGDfK))2	Integrin	Neurological Disease Cancer
E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .

HY-P6022

*G4RGDSP, integrin-binding peptide*	Integrin	Others
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology

HY-130119

Integrin-IN-2	Integrin	Cancer
Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC₅₀ values of 7.8, 8.4, 8.4 and 7.4, respectively .

HY-P1868

*α2β1 Integrin* Ligand Peptide** 3 Publications Verification DGEA peptide	Integrin	Infection
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC₅₀ values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .

HY-150124

K34c	Integrin Apoptosis	Cancer
K34c is a potent and selective α5β1 integrin antagonist. By inhibiting α5β1 integrin, K34c reduces chemotherapy-induced premature senescence and promotes apoptosis. K34c can be used in glioblastoma research .

HY-P990643

OS-2966	Integrin	Inflammation/Immunology
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-139702

*α5β1 integrin* agonist-1**	Integrin Apoptosis Caspase	Cancer
α5β1 integrin agonist-1 is an α5β1 integrin agonist, with an EC₅₀ of 1.5 nM. α5β1 integrin agonist-1 inhabits α4β1 integrin (IC₅₀ = 2.99 μM) in Jurkat/VCAM-1 adhesion assayα5β1 integrin agonist-1 induces concentration-dependent apoptosis and activates the caspase 3/7 pathway in α5β1 integrin-expressing K562 cancer cells. α5β1 integrin agonist-1 can be used for the study of cancer .

HY-P2532

Integrin Binding Peptide	Integrin	Others
Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation .

HY-18668

Integrin antagonist 27	Integrin	Cancer
Integrin antagonist 27 (Compound 27) is a small molecule integrin αvβ3 antagonist with an affinity of 18 nM. Integrin antagonist 27 can be combined with Paclitaxel (HY-B0015) to selectively target αvβ3-positive metastatic cancer cells. Integrin antagonist 27 is used as an anticancer agent .

HY-P1868A

*α2β1 Integrin* Ligand Peptide TFA** 3 Publications Verification DGEA peptide TFA	Integrin	Others
α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-129453

BOP sodium	Integrin	Inflammation/Immunology
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .

HY-P4896

FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro	Integrin	Cancer
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an *integrin* inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .

HY-W008201

tert-Butyl 3-formylpyrrolidine-1-carboxylate	Drug Intermediate	Inflammation/Immunology
tert-Butyl 3-formylpyrrolidine-1-carboxylate is a drug intermediate that can be used for the synthesis nonpeptidic αvβ6 Integrin inhibitors .

HY-P10045

Integrin signaling inhibitor, mP13	Integrin	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-P1930A

Risuteganib hydrochloride	Integrin	Inflammation/Immunology
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-P11339

c-RGD-SH	Integrin	Cancer
c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-119677

Oxypertine WIN-18501-2	5-HT Receptor Dopamine Receptor	Neurological Disease
Oxypertine (WIN-18501-2) is a neuroprotective agent. Oxypertine shows high affinity for the 5-HT2 and dopamine D2 receptors with K_is of 8.6 nM and 30 nM, respectively. Oxypertine can be used in the research of neurological conditions, such as anxiety and schizophrenia .

HY-161730

*αvβ1 integrin-IN-3*	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect .

HY-P990207

*Anti-Mouse/Human Integrin* β7 Antibody (FIB504)**	Integrin	Neurological Disease Inflammation/Immunology Cancer
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is an anti-mouse/human Integrin β7 IgG2a monoclonal antibody. Anti-Mouse/Human Integrin β7 Antibody (FIB504) can reduce the residence of type 2 innate lymphoid cells (ILC2s). Anti-Mouse/Human Integrin β7 Antibody (FIB504) can be used for researches on inflammation conditions and cancer such as lupus nephritis and glioma .

HY-P991644

IMGN388 Antibody	Integrin ADC Antibody	Cancer
IMGN388 Antibody is an *Integrin* targeting humanized monoclonal antibody. IMGN388 Antibody can be used for synthesis ADCs .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-175288

*αMβ2 integrin* agonist-1**	Integrin JNK ERK	Inflammation/Immunology Cancer
αMβ2 integrin agonist-1 (Compound 8) is a highly selective αMβ2 integrin agonist with anti-inflammatory activity (EC₅₀=1.4 nM). αMβ2 integrin agonist-1 activates integrin-mediated cell adhesion and JNK/ERK signaling. αMβ2 integrin agonist-1 induces tumor-associated macrophage repolarization and enhances antitumor T-cell immune responses. αMβ2 integrin agonist-1 is promising for research of cancers and chronic inflammatory diseases (e.g., pancreatic cancer, rheumatoid arthritis) .

HY-153807

*αvβ6 integrin* inhibitor 2**	Integrin	Inflammation/Immunology
αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC₅₀ of 96.5 nM (WO2020081154A1, example 19) .

HY-107147

CLT-28643	Integrin	Others
CLT-28643 is an integrin α5β1 inhibitor. CLT-28643 can inhibit the high expression of integrin α5β1 in the bleb at early time-points after surgery and promote wound healing process .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P3160

Fibronectin 5+ Cited Publications	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Integrin
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans . This product is a human Fibronectin obtained by recombinant expression in a rice expression system.

HY-N0031

Plantamajoside 2 Publications Verification	Plantaginaceae Classification of Application Fields Simple Phenylpropanols Phenols Polyphenols Phenylpropanoids Plantago asiatica L. Plants Inflammation/Immunology Disease Research Fields Source Classification	NF-κB PI3K Akt Apoptosis Autophagy p38 MAPK Src
Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Phenols Endogenous metabolite Disease Research Fields Source Classification Cancer	Integrin Endogenous Metabolite
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-N2587

Irigenin	Flavonoids Iridaceae Classification of Application Fields Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields Isoflavones Source Classification Cancer	Integrin Apoptosis
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-113439

12-HETE 2 Publications Verification	Microorganisms Source Classification	Apoptosis
12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .

HY-B0665

Fibrin	Cardiovascular Disease Natural Products Animals Disease Research Fields Source Classification Cancer	Integrin
Fibrin is an insoluble protein isolated from bovine blood that is produced in response to bleeding. As the main component of blood clots, fibrin functions in blood coagulation. Fibrin binds to the integrins ICAM-1, VE-cadherin, αIIbβ3, αMβ2, αvβ3 and α5β1. Fibrin is used in research related to chronic wounds .

HY-W654264

2-Methylbutyrylcarnitine chloride	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Integrin
2-Methylbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. 2-Methylbutyrylcarnitine (chloride) enhances platelet hyperreactivity and thrombus formation in mice. 2-Methylbutyrylcarnitine (chloride) is a branched-chain acylcarnitine .

HY-W008859R

Tetrac (Standard) Tetraiodothyroacetic acid (Standard); 3,3',5,5'-Tetraiodothyroacetic acid (Standard)	Structural Classification Monophenols Ketones, Aldehydes, Acids Phenols Endogenous metabolite Source Classification	Reference Standards Integrin Endogenous Metabolite
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-136699

Excisanin A	Terpenoids Labiatae Hymenaea verrucosa Gaertn. Diterpenoids Plants Source Classification	MMP FAK Src Integrin
Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer .

HY-122552

Chrysotobibenzyl	Natural Products Orchidaceae Plants Dendrobium pulchellum Roxb. et Lindl. :Lindl. Source Classification	Integrin
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394) .

HY-N2587R

Irigenin (Standard)	Structural Classification Flavonoids Iridaceae Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Isoflavones Source Classification	Reference Standards Integrin Apoptosis
Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-N0031R

Plantamajoside (Standard)	Plantaginaceae Structural Classification Simple Phenylpropanols Phenols Polyphenols Phenylpropanoids Plantago asiatica L. Plants Source Classification	Reference Standards NF-κB PI3K Apoptosis Autophagy p38 MAPK Src
Plantamajoside (Standard) is the analytical standard of Plantamajoside. This product is intended for use in research and analytical applications. Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

Cat. No.	Product Name	Chemical Structure

HY-113439S

12-HETE-d8 2 Publications Verification
12-HETE-d₈ is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .

HY-P3448S

Certepetide-13C6,15N2

Certepetide- ¹³C₆, ¹⁵N₂ (CEND-1- ¹³C₆, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-19344S2

Lifitegrast-d4-1

Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-P3448S1

Certepetide-13C2,15N

Certepetide- ¹³C₂, ¹⁵N (CEND-1- ¹³C₂, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-152003S

Ganglioside GM2-d3 ammonium

Ganglioside GM2-d₃ (ammonium) is the deuterium labeled Ganglioside GM2 (HY-148385). Ganglioside GM2 is a human tumor antigen predominantly found in human tumor cells and fetal brain tissue. As a sialylated glycosphingolipid, Ganglioside GM2 is involved in processes such as cell signaling, adhesion, and motility. Ganglioside GM2 abnormal expression and accumulation are associated with tumors and neurodegenerative disorders. Ganglioside GM2 promotes tumor cell migration and invasion by directly binding to the integrin β1 receptor, activating the FAK/Src/Erk-MAPK signaling pathway, and inducing actin cytoskeleton remodeling .

HY-19344S1

Lifitegrast-d6

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4

Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks